The Norwegian Institute of Public Health, known as FHI, will release a comprehensive report on the long-term effects of the weight-loss drug semaglutide on March 20, 2026. This drug is sold under the brand name Wegovy. The report has been highly anticipated by both patients and doctors across Norway who are seeking clearer guidance.
The study followed a group of five thousand patients over a period of two years. Preliminary data from the research suggests there may be an increased risk of thyroid cancer associated with the medication. The full and final findings from the extensive study are still pending and will be detailed in the upcoming report.
FHI director Camilla Stoltenberg provided a statement regarding the report's significance. According to the announcement, Stoltenberg said, 'This report will provide important information for patients and healthcare providers.' The release is expected to offer crucial data to help inform medical decisions and patient care.
The scheduled release in 2026 marks a key milestone for public health monitoring in Norway. The findings will contribute to the broader understanding of pharmaceutical safety and long-term patient outcomes.